PTGFR and open-angle glaucoma: Prostanoid FP receptor agonists derived from prostaglandin F2α are the primary choice for medical treatment of primary open-angle glaucoma (POAG), primarily because of their significant efficacy in reducing intraocular pressure (IOP) and their convenient dosing schedule requiring infrequent application [1].